You are viewing: Rest Of Europe AI in Oncology Market analysis
Part of: AI in Oncology Market (Global)

The Rest Of Europe AI in Oncology Market was valued at $129.2 Million in 2024 and projected to reach to $574.8 Million by 2029, representing a compound annual growth rate of 28.2%. Rest Of Europe's AI in Oncology market is positioned for exceptional growth through 2029, driven by advancing healthcare digitalization, increasing cancer prevalence, and rising demand for efficient diagnostic solutions.

Rest Of Europe AI in Oncology Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Europe AI in Oncology Market Trends and Insights

  • This 28.2% compound annual growth rate reflects accelerating adoption of artificial intelligence solutions across oncology diagnostics, treatment planning, and patient management in the region.
  • Rest Of Europe is capitalizing on increasing healthcare digitalization, rising cancer incidence, and regulatory support for AI-driven medical technologies. The market in Rest Of Europe is driven by growing investments in healthcare infrastructure, collaboration between academic institutions and technology providers, and heightened awareness of AI's potential to improve oncology outcomes.
  • Rest Of Europe's healthcare systems are increasingly integrating machine learning algorithms for tumor detection, pathology analysis, and personalized treatment recommendations.
  • Between 2024 and 2029, Rest Of Europe is expected to see significant deployment of AI platforms across hospitals, diagnostic centers, and research facilities, supported by favorable reimbursement policies and cross-border healthcare initiatives..

Key Market Statistics

  • CAGR (2024-2029) 28.2% CAGR
  • Market Size, 2024 ~USD 129.2 Million
  • Forecast, 2029 ~USD 574.8 Million
  • Country Rest Of Europe

Rest Of Europe AI in Oncology Market Overview

Rapid Market Expansion :

Rest Of Europe's AI in Oncology market is growing at 28.2% CAGR, expanding from $129.2 million in 2024 to $574.8 million by 2029, driven by increasing adoption of AI-powered diagnostic and treatment solutions across the region.

Diagnostic AI Leadership :

European healthcare systems are increasingly deploying AI algorithms for early cancer detection and pathology analysis, with Rest Of Europe emerging as a key adoption hub for machine learning-based imaging solutions in oncology centers.

Regulatory Support & Healthcare Investment :

Rest Of Europe benefits from supportive healthcare policies, EU digital health initiatives, and substantial investments in medical technology infrastructure, accelerating AI integration in cancer care facilities and research institutions.

Treatment Personalization Focus :

Healthcare providers in Rest Of Europe are leveraging AI for precision oncology, treatment planning optimization, and patient outcome prediction, reflecting a shift toward data-driven, personalized cancer management approaches.

Rest Of Europe AI in Oncology Market Dynamics

  • The region's healthcare systems are actively integrating AI technologies to improve clinical outcomes, reduce treatment costs, and enhance patient management capabilities.
  • Collaborative efforts between government health agencies, research institutions, and technology providers are accelerating innovation adoption across oncology departments. The market expansion is supported by growing awareness of AI's clinical benefits, improved reimbursement policies for AI-assisted diagnostics, and substantial R&D investments in European biotech and healthtech sectors.
  • Rest Of Europe's strong healthcare infrastructure and regulatory framework create favorable conditions for sustained market growth, with emerging opportunities in predictive analytics, drug discovery acceleration, and real-world evidence generation for cancer treatment protocols..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • Rest Of Europe's AI in Oncology Market is valued at $129.2 million in 2024 and will grow to $574.8 million by 2029, representing a 28.2% CAGR.
      • Rest Of Europe is witnessing accelerated adoption of AI-powered diagnostic and treatment planning tools across oncology centers and hospitals.
      • Rest Of Europe benefits from strong healthcare infrastructure investments and regulatory frameworks supporting AI integration in medical practice.
      • Rest Of Europe's market growth is fueled by rising cancer prevalence, digital health initiatives, and increasing collaboration between healthcare providers and AI technology vendors.

      AI in Oncology Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment DEEP LEARNING (Type)
      Forecast Period 2024-2029
      Growth Rate CAGR of 29.4% from 2024 to 2029
      Largest Segment SOLID TUMORS (Cancer Type)
      Market Size Base Year (Billions) ~USD 2.45 (2024)
      Revenue Forecast (Billions) ~USD 8.9 (2029)
      Segments Covered Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model

      Rest Of Europe AI in Oncology Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Technology

      • Computer Vision
      • Context-Aware Processing & Computing
      • Image Analysis
      • Machine Learning
      • Natural Language Processing
      • Natural Language Processing (Nlp)

      By Type

      • Adaptive Trial Design & Monitoring
      • AI-Guided Drug Delivery
      • Brain Tumors
      • Breast Cancer
      • Candidate Selection & Validation
      • Chemotherapy
      • Clinical Trial Optimization
      • Colorectal Cancer
      • Combination & Dose Optimization
      • Computed Tomography
      • Computed Tomography (Ct)
      • Deep Learning
      • Digital Pathology & Histopathology
      • Genetic Risk Prediction
      • Hit Identification & Prioritization
      • Hit-To-Lead Identification/Lead Generation
      • Hospitals & Clinics
      • Imaging & Radiology
      • Immunotherapy
      • Intraoperative Guidance & Robotics
      • Intraoperative Guidance And Robotics
      • Laboratories & Diagnostic Centers
      • Lead Optimization
      • Leukemia
      • Liquid Biopsy & Biomarker Detection
      • Long-Term Prediction
      • Lung Cancer
      • Lymphoma
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mental Health & Support Systems
      • Multiple Myeloma
      • Nuclear Imaging
      • Other Healthcare Providers
      • Other Hematologic Malignancies
      • Other Hematological Malignancies
      • Other Imaging Modalities
      • Other Machine Learning Technologies
      • Other Solid Tumors
      • Other Tumors
      • Others Healthcare Providers
      • Patient Education & Empowerment
      • Personalized Treatment Planning
      • Postoperative Analysis & Recovery
      • Precision Medicine & Genomic Analysis
      • Preclinical Testing
      • Predictive Modeling For Human Trials
      • Predictive Modelling For Human Trials
      • Predictive Models For Treatment Response
      • Preoperative Imaging & 3D Modeling
      • Preoperative Imaging And 3D Modeling
      • Prostate Cancer
      • Radiation Therapy
      • Radiomics & Radiogenomics
      • Radiomics And Radiogenomics
      • Recurrence Monitoring
      • Reinforcement Learning
      • Remote Patient Monitoring
      • Specialty Centers
      • Supervised Learning
      • Surgical Planning & Assistance
      • Symptom Management & Virtual Assistance
      • Target Identification & Validation
      • Targeted Therapy
      • Treatment Recommendation Systems
      • Ultrasound
      • Unsupervised Learning
      • X-Ray Imaging

      By Application

      • Data Management & Analytics
      • Diagnosis & Early Detection
      • Drug Development
      • Drug Discovery
      • Other Applications
      • Patient Engagement & Remote Monitoring
      • Post Treatment Surveillance & Survivorship Care
      • Post-Treatment Surveillance & Survivorship Care
      • Treatment Planning & Personalization

      By Cancer Type

      • Hematologic Malignancies
      • Hematological Malignancies
      • Other Cancer Types
      • Other Cancers
      • Others Cancer Types
      • Solid Tumors

      By End User

      • Academic & Research Institutions
      • Government & Regulatory Agencies
      • Healthcare Payers
      • Healthcare Providers
      • Medical Device/ Equipment Companies
      • Medical Device/Equipment Companies
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      By Player Type

      • Business Process Service Providers
      • Integrated Suite/Platform Providers
      • Niche/Point Solution Providers
      • Technology Providers

      By Deployment Model

      • Cloud-Based Model
      • Hybrid Model
      • On-Premises Model

      Target Audience

      • Healthcare Technology Investors : Investment firms and venture capitalists seeking to identify high-growth AI oncology opportunities in Rest Of Europe need regional market data, growth projections, and competitive analysis to guide funding decisions and portfolio development.
      • Medical Device & Software Companies : Oncology AI solution providers require detailed Rest Of Europe market intelligence, including adoption rates, regulatory requirements, reimbursement pathways, and customer segments to develop localized go-to-market strategies.
      • Healthcare System Administrators : Hospital networks and cancer center leaders in Rest Of Europe need market insights on AI solution effectiveness, implementation best practices, cost-benefit analyses, and vendor comparisons to make informed technology procurement decisions.
      • Pharmaceutical & Biotech Companies : Drug developers and biotech firms leveraging AI for oncology research and clinical trials require Rest Of Europe market data to understand AI adoption in healthcare systems, clinical trial infrastructure, and precision medicine opportunities.
      • Healthcare Consultants & Analysts : Management consulting firms and healthcare research organizations need comprehensive Rest Of Europe AI oncology market data to support client advisory services, strategic planning, and competitive benchmarking across the region.

      Reasons to Buy this Report

      • Regional Market Sizing & Forecasts : Obtain precise market valuation data specific to Rest Of Europe, including 2024 baseline ($129.2M) and 2029 projections ($574.8M), enabling accurate business planning and investment decisions tailored to regional growth trajectories.
      • Competitive Landscape Intelligence : Identify key AI oncology solution providers, technology leaders, and emerging startups operating in Rest Of Europe, understanding market positioning, partnerships, and competitive dynamics unique to the region.
      • Regulatory & Reimbursement Insights : Access detailed analysis of Rest Of Europe's healthcare policies, AI regulatory frameworks, reimbursement models, and government initiatives that directly impact market adoption and commercial viability of oncology AI solutions.
      • End-User Adoption Patterns : Understand how hospitals, cancer centers, and diagnostic labs in Rest Of Europe are implementing AI technologies, including adoption barriers, success factors, and clinical integration strategies specific to regional healthcare systems.
      • Growth Opportunity Mapping : Discover high-potential segments within Rest Of Europe's oncology AI market, including emerging applications in treatment planning, patient monitoring, and drug discovery, with actionable insights for market entry and expansion strategies.

      Frequently asked questions

      What is the current market size of AI in Oncology in Rest Of Europe?

      Rest Of Europe's AI in Oncology Market was valued at $129.2 million in 2024 and is projected to reach $574.8 million by 2029.

      What is the expected growth rate for AI in Oncology in Rest Of Europe?

      Rest Of Europe's AI in Oncology Market is expected to grow at a compound annual growth rate (CAGR) of 28.2% from 2024 to 2029.

      Which applications of AI are most prevalent in Rest Of Europe's oncology market?

      Rest Of Europe is seeing significant adoption of AI for tumor detection, pathology image analysis, treatment planning optimization, and patient outcome prediction in oncology settings.

      What factors are driving AI adoption in Rest Of Europe's oncology sector?

      Rest Of Europe's market growth is driven by rising cancer incidence, healthcare digitalization initiatives, regulatory support for AI technologies, and increased investment in medical infrastructure.

      How is Rest Of Europe positioned compared to other European regions in AI oncology adoption?

      Rest Of Europe represents a significant portion of the broader European AI in Oncology Market, with strong growth momentum supported by diverse healthcare systems and technology partnerships across multiple countries.

      RESEARCH METHODOLOGY

      The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

      Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

      Primary Research

      In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

      After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

      In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

      Breakdown of Primary Participants:

      AI in Oncology Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry and markets have been identified through extensive secondary research.
      • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      AI in Oncology Market

      Data Triangulation

      After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

      Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

      • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
      • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
      • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

      Stakeholders

      • Clinical/Physician Centers
      • AI Providers
      • Clinical Research Organizations
      • Pharmaceutical/Biopharmaceutical Companies
      • Research and Development (R&D) Companies
      • Business Research and Consulting Service Providers
      • Medical Research Laboratories
      • Academic Medical Centers/Universities/Hospitals
      • Government Agencies
      • Regulatory Agencies
      • Clinical Researchers
      • Clinical Research Organizations
      • Accountable Care Organizations
      • Investors and Venture Capitalists

      Report Objectives

      • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
      • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
      • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
      • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
      • To profile the key players and comprehensively analyze their market sizes and core competencies
      • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

      Get the Full AI in Oncology Market Report

      Full forecast, segment splits, and company analysis for all AI in Oncology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status